Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.
Michael J MorrisSteven P RoweMichael A GorinLawrence SapersteinFrédéric PouliotDavid JosephsonJeffrey Y C WongAustin R PantelSteve Y ChoKenneth L GageMorand PiertAndrei H IagaruJanet H PollardVivien WongJessica JensenTess LinNancy StamblerPeter R CarrollBarry A Siegelnull nullPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Performance of 18F-DCFPyL-PET/CT achieved the study's primary endpoint, demonstrating disease localization in the setting of negative standard imaging and providing clinically meaningful and actionable information. These data further support the utility of 18F-DCFPyL-PET/CT to localize disease in men with recurrent prostate cancer.See related commentary by True and Chen, p. 3512.